|
 |
 Home > Available Issues |
|
|
 Original Articles |
| Clinical Studies on Augmentin |
| Sung Kyung Kim*, Wan Shik Shin*, Moon Won Kang*, Hee Young Chung*, Min Ja Kim**, Myung Suck Lee**, Young Hoon Kim**, Seung Chul Park** |
| Department of Internal Medicine, Catholic Medical College*,
Department of Internal Medicine, College of Medicine, Korea University**, Seoul, Korea |
Vol.18 Num.1 (p63~68)
|
|
|
Augmentin is a combination drug consisting of β-lactam antibiotic, amoxicillin, and β-lactamase inhibitor, clavulanic acid. Augmentin is active against ampicillin-resistant strains of S. aureus, E. coli, K. pneumoniae, P. mirabilis, B. fragilis, S. typhi due to inhibition of β-lactamase by clavulanic acid.
Augmentin was given per orally to 56 patients with various infection: 35 with respiratory tract infection, 17 with urinary tract infection, 4 with typhoid or paratyphoid fever.
The clinical response was satisfactory in 32(94%) of 35 patients with respiratory tract infection, 17(100%) of 17 with urinary tract infection, 4(100%) of 4 with typhoid or paratyphoid fever. Overall, Augmentin was effective in 54(98%) of all patients treated. 12 of 27 isolated organisms were resistant to ampicillin, but sensitive to augmentin except 1 strain of P. aeruginosa.
Adverse effects observed 7(12.5%) of 56 patients included mild abdominal pain, diarrhea, nausea, and rash. But it is doubtful whether these adverse effects are related to augmentin or not.
|
|
|
Keywords : |
|
|
|
|
|
|
|
|
